Global Nucleic Acid Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

According to our latest research, the global Nucleic Acid Drugs market size will reach USD 243.8 million in 2030, growing at a CAGR of 17.6% over the analysis period.

Nucleic Acid Drugs are pharmaceutical compounds that target nucleic acids (DNA or RNA) for therapeutic purposes, including gene therapy and antisense therapy.

The Nucleic Acid Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Market segmentation

Nucleic Acid Drugs market is split by Type and by Application. For the period 2024-2030, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Antisense Nucleic Acid Drugs
siRNA Drugs
saRNA Drugs
miRNA Drugs
mRNA Drugs
other

Market segment by Application, can be divided into
Genetic Disease
Cancer
Cardiovascular Diseases
Other

Market segment by players, this report covers
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Mina Therapeutics
BioNTech
NeXstar Pharmaceuticals
Nippon Shinyaku
Moderna Therapeutics
CureVac
Regulus Therapeutics
Miragen Therapeutics

Market segment by regions, regional analysis covers
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)
South America
Middle East & Africa

The content of the study subjects, includes a total of 8 chapters:

Chapter 1, to describe Nucleic Acid Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Nucleic Acid Drugs, with recent developments and future plans

Chapter 3, the Nucleic Acid Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4, to break the market size data at the region level, with key companies in the key region and Nucleic Acid Drugs market forecast, by regions, with revenue, from 2024 to 2030.

Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2024 to 2030.

Chapter 7 and 8, to describe Nucleic Acid Drugs research findings and conclusion, appendix and data source.